Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia.

Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia. Oncol Rep. 2019 Feb 06;: Authors: Pang Y, Li H, Gong Y, Jing S, Peng C, Liu W, Zhao Y, Wang H, Kaushik D, Rodriguez R, Wang Z Abstract Benign prostatic hyperplasia (BPH) is a common chronic disease in older males. The pathogenesis of BPH remains elusive but may be associated with chronic inflammation. Chemokines and chemokine receptors have been implicated as critical mediators in the immune response and inflammatory processes. In the present study, the aim was to evaluate the association of three polymorphisms in chemokine genes, namely C‑C motif chemokine ligand (CCL)2 rs1024611, CC chemokine receptor 2 (CCR2) rs1799864 and CCL5 rs2107538, with BPH risk. These polymorphisms were genotyped in 109 patients with BPH and 160 control subjects, using the polymerase chain reaction and multiple ligase detection reaction method. The CCL5 rs2107538 polymorphism was identified to be associated with a significantly lower risk of BPH [A/G vs. G/G: odds ratio (OR)=0.37, 95% confidence interval (CI)=0.17‑0.78; A/A + A/G vs. G/G: OR=0.39, 95% CI=0.19‑0.79; A vs. G: OR=0.58, 95% CI=0.35‑0.96). However, this polymorphism was also associated with the development of larger prostate volumes in patients with BPH (A/G vs. G/G: OR=3.02, 95% CI=1.28‑7.11; AA + AG vs. GG: OR=2.83, 95% CI=1.28‑6.26; A vs. G: OR=1.94...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Authors: Liu J, Li Y, Yang D, Yang C, Mao L Abstract In recent years, with the westernization of lifestyle, reduced physical activity and increased prostate-specific antigen (PSA) testing, the incidence of prostate cancer (PCa) has risen significantly in developing countries. Currently, PSA is the only PCa biomarker applied clinically, but it does not perform well in the early diagnosis and distinguishing between benign prostatic hyperplasia and prostate cancer. With the advances in deep sequencing technology, a series of new PCa biomarkers have been recently proposed to improve the diagnostic value of PSA, such as...
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery.Materials and methodsBy immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples.ResultsOur results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, ...
Source: Andrology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Conclusion: This study reported the first case of isolated rare urethral metastasis from primary lung adenocarcinoma and underlined the necessity for clinicians to remain vigilant to metastasis during follow-up of primary cancer.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
PMID: 31424029 [PubMed - as supplied by publisher]
Source: Asian Journal of Andrology - Category: Urology & Nephrology Authors: Tags: Asian J Androl Source Type: research
ConclusionsT. tuberosum has been tested for various biological activities and the extracts (tubers in particular) demonstrated a promising potential as an antibacterial, antioxidant, anti-inflammatory and inhibitors of benign prostatic hyperplasia. A lack of alignment between the ethno-medicinal uses and existing biological screenings was observed, indicating the need to explore its potential for the treatment against respiratory affections, urinary affections and blood diseases. Likewise, it is necessary to analyse deeply the relationship that exists between the different tuber colours of T. tuberosum and its use for the ...
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Journal of Endourology, Ahead of Print.
Source: Journal of Endourology - Category: Urology & Nephrology Authors: Source Type: research
This study determined whether or not benign prostatic hyperplasia (BPH) induced by a high-fat diet (HFD) is involved in inflammatory responses, apoptosis, and the signal transducer and activator of transcription (STAT3)/nuclear factor-kappa B (NF-κB)- and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress pathways. Forty rats were divided into four groups: control; HFD; testosterone; and HFD+testosterone. Hematoxylin and eosin (HE) staining was used to assess histologic changes. An enzyme-linked immunosorbent assay and Western blot analysis were used to detect levels of related proteins. Com...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
CUPERTINO, Calif., Aug. 13, 2019 -- (Healthcare Sales &Marketing Network) -- Corinth MedTech, a medical device company and the developer of the Veloxion™ System for relieving the symptoms of BPH (Benign Prostatic Hyperplasia) and TURBT (Transurethral Res... Devices, Urology, Personnel Corinth MedTech, Veloxion, Benign Prostatic Hyperplasia, TURBT
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Voiding symptoms in benign prostatic hyperplasia (BPH) are driven by prostate smooth muscle contraction and prostate growth. Smooth muscle contraction in the prostate and other organs critically depends on activation of the small monomeric GTPase RhoA and probably Rac1. A role of another GTPase, ADP-ribosylation factor 6 (ARF6), for smooth muscle contraction has been recently suggested by indirect evidence but remains to be proven for any organ. Here, we report effects of NAV2729, an inhibitor with assumed specificity for ARF6, in human prostate tissues and cultured prostate stromal cells (WPMY-1). NAV2729 (5 μm) inhibi...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
CONCLUSION: The VIRTUE © sling seems to be an effective, safe tool treating SUI at short term. LEVEL OF EVIDENCE: 3. PMID: 31387835 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
More News: Benign Prostatic Hyperplasia | Cancer & Oncology | Genetics | Study